SYRA vs LFMD

For growth investors, LifeMD, Inc.

(LFMD) is the stronger pick with -8. 7% revenue growth year-over-year, versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, LifeMD, Inc.

(LFMD) delivered a total return of -45. 8%, compared to -83. 3% for Syra Health Corp. Class A Common Stock (SYRA). Over 10 years, the gap is even starker: LFMD returned +220. 7% versus SYRA's -83. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Syra Health Corp.

Class A Common Stock (SYRA) is the lower-risk stock at 0. 19β versus LifeMD, Inc. 's 2. 12β — meaning LFMD is approximately 1037% more volatile than SYRA relative to the S&P 500. On balance sheet safety, Syra Health Corp. Class A Common Stock (SYRA) carries a lower debt/equity ratio of 7% versus 27% for LifeMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LifeMD, Inc.

(LFMD) is pulling ahead at -8. 7% versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). On earnings-per-share growth, the picture is similar: Syra Health Corp. Class A Common Stock grew EPS 85. 5% year-over-year, compared to 56. 6% for LifeMD, Inc.. Over a 3-year CAGR, LFMD leads at 17. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LifeMD, Inc.

(LFMD) is the more profitable company, earning -3. 7% net margin versus -12. 4% for Syra Health Corp. Class A Common Stock — meaning it keeps -3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LFMD leads at -4. 0% versus -12. 5% for SYRA. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, LFMD (1.

5% yield) pays a dividend. SYRA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Syra Health Corp.

Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19)). LifeMD, Inc. (LFMD) carries a higher beta of 2. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYRA: -83. 3%, LFMD: +220. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LFMD pays a dividend while SYRA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.